Voluntary announcement phase iii clinical study data of anaprazole sodium for reflux esophagitis presented at ueg week 2026PRESENTED at ueg week 2026
Filed with HKEX · Stock code 2575 ·
6ix is reading this filing.
View original source (HKEXnews)Xuanzhu Biopharmaceutical Co., Ltd. on 6ix
Earlier from Xuanzhu Biopharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement unusual price movements
- 2025 Annual report - supplemental information
- 2026 Interim report
- Voluntary announcement first patient enrolled in phase III clinical trial of anaprazole sodium for helicobacter pylori eradication
Follow Xuanzhu Biopharmaceutical into a list and get an email when it puts out news.
Follow Xuanzhu Biopharmaceutical